Arixa Pharmaceuticals Announces Acquisition by Pfizer
Arixa Pharmaceuticals™, Inc., a company dedicated to developing next-generation oral antibiotics for drug-resistant Gram-negative infections today announced that Pfizer’s Hospital Business has agreed to acquire Arixa.
Arixa’s lead compound, ARX-1796, is an oral prodrug of avibactam, a beta lactamase inhibitor (BLI) that was FDA-approved in 2015 as part of Avycaz® (sold by Pfizer as Zaficefta® outside the United States), an intravenous-only combination with ceftazidime for the treatment of a number of indications caused by Gram-negative pathogens. Arixa Co-Founder and CSO Dr. Eric M. Gordon led a team to address the challenge of creating a viable prodrug of avibactam with now-patented chemistry. As a result of Arixa’s now patented chemistry, the prodrug of avibactam was 60-80% absorbed when administered orally to humans in a Phase 1 clinical trial, releasing the FDA-approved avibactam molecule in the bloodstream. In contrast, ~7% of the intravenous compound is absorbed orally. Combined with an antibiotic such as ceftibuten, Arixa’s ARX-1796, if approved, opens the way for orally-available avibactam to be part of a next-generation, oral antibiotic combination for resistant urinary tract and other infections.
It is a great news for iNtRON as a global player is returning to the antibiotic market due to strong worries to the MDR Gram-negative bacterial infection. iNtRON is developing multi-pipelines for the treatment of MDR Gram-negative bacterial infections with iNtRON’s unique platform technology based on bacteriophage and phage-derived endolysin. iNtRON will be able to share more very soon regarding its very promising lead pipeline.
it is iNtRON.
if it is iNtRON?